IMU Stock Overview
A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Imugene Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.062 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.039 |
| Beta | 3.34 |
| 11 Month Change | 19.23% |
| 3 Month Change | -3.13% |
| 1 Year Change | -6.06% |
| 33 Year Change | -84.30% |
| 5 Year Change | 181.82% |
| Change since IPO | -36.41% |
Recent News & Updates
Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?
Aug 29
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
Apr 12Recent updates
Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?
Aug 29We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Sep 19We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
May 30Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Jan 30Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More
Nov 11Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Aug 22Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Feb 28A Look At Imugene's (ASX:IMU) CEO Remuneration
Feb 17
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years
Dec 24Shareholder Returns
| IMU | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 19.2% | -0.5% | 0.7% |
| 1Y | -6.1% | 16.0% | 10.5% |
Return vs Industry: IMU underperformed the Australian Biotechs industry which returned 16% over the past year.
Return vs Market: IMU underperformed the Australian Market which returned 10.5% over the past year.
Price Volatility
| IMU volatility | |
|---|---|
| IMU Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IMU has not had significant price volatility in the past 3 months.
Volatility Over Time: IMU's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Leslie Chong | www.imugene.com |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 for gastric cancer; VAXINIA is in phase 1 MAST trial for patients with metastatic or advanced solid tumours; and CHECKvacc oncolytic virotherapy is in phase 1 clinical trial against metastatic triple negative breast cancer.
Imugene Limited Fundamentals Summary
| IMU fundamental statistics | |
|---|---|
| Market cap | AU$455.70m |
| Earnings (TTM) | -AU$149.68m |
| Revenue (TTM) | n/a |
-65.8x
P/S Ratio-3.0x
P/E RatioIs IMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMU income statement (TTM) | |
|---|---|
| Revenue | -AU$6.93m |
| Cost of Revenue | AU$0 |
| Gross Profit | -AU$6.93m |
| Other Expenses | AU$142.76m |
| Earnings | -AU$149.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 100.00% |
| Net Profit Margin | 2,161.33% |
| Debt/Equity Ratio | 0% |
How did IMU perform over the long term?
See historical performance and comparison